Virios Stock Analysis

The current indifference towards the small price fluctuations of Virios Therapeutics may raise some interest from stockholders as it is trading at a share price of 0.0 on very low momentum in trading volume. The company directors and management did not add any value to Virios Therapeutics investors in December. However, most investors can still diversify their portfolios with Virios Therapeutics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to stockholders with longer-term investment horizons.
Check out World Market Map.

Virios Stock Analysis 

 
Refresh
The Virios Therapeutics stock analysis report makes it easy to digest most publicly released information about Virios Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Virios Stock analysis module also helps to analyze the Virios Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Virios Stock Analysis Notes

The book value of the company was at this time reported as 2.27. The company recorded a loss per share of 2.38. Virios Therapeutics had not issued any dividends in recent years. Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia. Virios Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. For more information please call the company at 866 620 8655 or visit https://www.virios.com.

Virios Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Virios Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Virios Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Virios Therapeutics is not yet fully synchronised with the market data
Virios Therapeutics has some characteristics of a very speculative penny stock
Net Loss for the year was (17.95 M).
Virios Therapeutics currently holds about 19.19 M in cash with (12.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.3.

Virios Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 54.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Virios Therapeutics's market, we take the total number of its shares issued and multiply it by Virios Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (106.95) % which means that it has lost $106.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (261.46) %, meaning that it created substantial loss on money invested by shareholders. Virios Therapeutics management efficiency ratios could be used to measure how well virios therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Virios Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Virios Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Virios Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Virios Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
De La Rosa Abel over two weeks ago via Macroaxis 
Purchase by De La Rosa Abel of 4000 shares of Virios Therapeutics
Pridgen William over two weeks ago via Macroaxis 
Virios Therapeutics exotic insider transaction detected
Whitley Richard James over a month ago via Macroaxis 
Purchase by Whitley Richard James of 200 shares of Virios Therapeutics
Duncan Gregory Scott over a month ago via Macroaxis 
Purchase by Duncan Gregory Scott of 5000 shares of Virios Therapeutics
Pridgen William over six months ago via Macroaxis 
Virios Therapeutics exotic insider transaction detected
Burch Richard Alan over six months ago via Macroaxis 
Acquisition by Burch Richard Alan of 7875 shares of Virios Therapeutics subject to Rule 16b-3
Duncan Gregory Scott over six months ago via Macroaxis 
Acquisition by Duncan Gregory Scott of 60000 shares of Virios Therapeutics subject to Rule 16b-3
Duncan Gregory Scott over six months ago via Macroaxis 
Purchase by Duncan Gregory Scott of 382 shares of Virios Therapeutics
Duncan Gregory Scott over six months ago via Macroaxis 
Purchase by Duncan Gregory Scott of 15675 shares of Virios Therapeutics
Pridgen William over six months ago via Macroaxis 
Exercise or conversion by Pridgen William of 801 shares of Virios Therapeutics subject to Rule 16b-3
Duncan Gregory Scott over a year ago via Macroaxis 
Acquisition by Duncan Gregory Scott of 21796 shares of Virios Therapeutics subject to Rule 16b-3
Duncan Gregory Scott over a year ago via Macroaxis 
Exercise or conversion by Duncan Gregory Scott of 801 shares of Virios Therapeutics subject to Rule 16b-3

Virios Therapeutics Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Virios Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Probability Of Bankruptcy Now

   

Probability Of Bankruptcy

Get analysis of equity chance of financial distress in the next 2 years
All  Next Launch Module
Check out World Market Map. Note that the Virios Therapeutics information on this page should be used as a complementary analysis to other Virios Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Tools for Virios Stock

When running Virios Therapeutics price analysis, check to measure Virios Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virios Therapeutics is operating at the current time. Most of Virios Therapeutics' value examination focuses on studying past and present price action to predict the probability of Virios Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Virios Therapeutics' price. Additionally, you may evaluate how the addition of Virios Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go